(firstQuint)Renal Transplantation and Raltegravir in HIV-Infected Patients.

 Antiretroviral treatment of HIV-1 Infection might interact with immunosuppressive treatments which increase rejection of renal graft incidence.

 In addition HIV infection may be modified together with cardiovascular risk.

 Patients participating to this study will receive after transplantation antiretroviral regimen including Raltegravir.

 Raltegravir treatment does not interact with immunosuppressive drugs and thus seems to be the treatment of choice to be associated with immunosuppressive drugs.

.

 Renal Transplantation and Raltegravir in HIV-Infected Patients@highlight

The aim of this study is to evaluate the incidence of acute renal graft rejection 6 months after transplantation in HIV-infected patients under three antiretroviral drugs regimen including Raltegravir.

